BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
US Department of Justice

Generated: September 25, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Biologically active B-chain homodimers
Abstract:Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the protein may have two substantially identical polypeptide chains, each of the chains being substantially homologous to the B-chain of PDGF. Alternatively, the protein may have two polypeptide chains that are substantially identical to the B-chain of PDGF. In addition, proteins comprising polypeptides that are variants or derivatives of the B-chain of PDGF are also disclosed. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm- blooded animals are also disclosed.
Inventor(s): Murray; Mark J. (Seattle, WA), Kelly; James D. (Seattle, WA)
Assignee: ZymoGenetics, Inc. (Seattle, WA)
Filing Date:Mar 18, 1992
Application Number:07/852,905
Claims:1. A therapeutic composition comprising a protein homodimer of human PDGF B-chain polypeptides, said protein being essentially free of the A-chain of PDGF, in combination with factor XIII and a physiologically acceptable carrier or diluent.

2. The therapeutic composition of claim 1, further comprising fibronectin.

3. The therapeutic composition of claim 1, further comprising albumin.

4. The therapeutic composition of claim 1, further comprising a protease inhibitor.

5. The therapeutic composition of claim 1, further comprising fibronectin and a protease inhibitor.

6. The therapeutic composition of claim 5, further comprising albumin.

7. The therapeutic composition of claim 1, further comprising a protein selected from the group consisting of TGF.alpha., TGF.beta., EGF, FGF, platelet factor 4, insulin, somatomedin and angiogenesis factor.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Daiichi Sankyo
Argus Health
Queensland Health
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus